Venrock Adviser, LLC — 13F Holdings & Portfolio

CIK 1615982 · latest 13F-HR filed 2026-08-14

Venrock Adviser, LLC manages $3.30B in 13F-reported U.S. long-equity assets across 33 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are APGE (34.18%), ORKA (11.97%), ERAS (9.94%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 4 new positions and exited 4; 18 existing positions rose in reported value and 6 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$3.30B

Long-equity book

Holdings
33

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+4 / −4 / ↑18 / ↓6

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 80.4%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Venrock Adviser, LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 APOGEE THERAPEUTICS INC APGE 03770N101 $1.13B 34.18% 8,493,321 SH
2 ORUKA THERAPEUTICS INC ORKA 687604108 $394.8M 11.97% 4,148,428 SH
3 ERASCA INC ERAS 29479A108 $327.8M 9.94% 17,891,812 SH
4 SPYRE THERAPEUTICS INC SYRE 00773J202 $265.0M 8.04% 2,985,448 SH
5 DIANTHUS THERAPEUTICS INC DNTH 252828108 $115.0M 3.49% 1,180,000 SH
6 OCULAR THERAPEUTIX INC OCUL 67576A100 $101.6M 3.08% 10,346,926 SH
7 DAMORA THERAPEUTICS INC DMRA 36322Q206 $93.7M 2.84% 3,603,595 SH
8 SAVARA INC SVRA 805111101 $90.8M 2.75% 14,745,943 SH
9 JADE BIOSCIENCES INC JBIO 008064206 $71.6M 2.17% 3,220,364 SH
10 COGENT BIOSCIENCES INC COGT 19240Q201 $63.6M 1.93% 1,642,166 SH
11 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $59.8M 1.81% 3,257,917 SH
12 VOR BIOPHARMA INC VOR 929033207 $56.0M 1.70% 3,041,719 SH
13 DYNE THERAPEUTICS INC DYN 26818M108 $48.3M 1.46% 2,173,913 SH
14 MAZE THERAPEUTICS INC MAZE 578784100 $47.8M 1.45% 1,602,034 SH
15 RELMADA THERAPEUTICS INC RLMD 75955J402 $47.4M 1.44% 6,844,305 SH
16 ORIC PHARMACEUTICALS INC ORIC 68622P109 $46.8M 1.42% 4,319,765 SH
17 CRESCENT BIOPHARMA INC. CBIO G2545C104 $38.4M 1.16% 2,133,576 SH
18 ZURA BIO LTD ZURA G9TY5A101 $38.0M 1.15% 6,434,990 SH
19 ADLAI NORTYE LTD ANL 00704R109 $36.9M 1.12% 3,212,731 SH
20 ENLIVEN THERAPEUTICS INC ELVN 29337E102 $26.7M 0.81% 526,331 SH
21 CYBIN INC HELP 23256X407 $25.5M 0.77% 3,851,654 SH
22 CULLINAN THERAPEUTICS INC CGEM 230031106 $25.1M 0.76% 1,379,965 SH
23 CENTURY THERAPEUTICS INC IPSC 15673T100 $21.3M 0.65% 8,695,652 SH
24 ARTIVA BIOTHERAPEUTICS INC ARTV 04317A107 $19.8M 0.60% 2,043,596 SH
25 CYTOMX THERAPEUTICS INC CTMX 23284F105 $18.7M 0.57% 4,982,124 SH
26 ACHIEVE LIFE SCIENCE INC QUIT 004468500 $18.0M 0.54% 2,751,032 SH
27 PARABILIS MEDICINES INC PBLS 698955101 $17.1M 0.52% 625,000 SH
28 SURROZEN INC SRZN 86889P208 $16.4M 0.50% 632,931 SH
29 KORRO BIO INC KRRO 500946108 $13.3M 0.40% 1,009,500 SH
30 ALTO NEUROSCIENCE INC ANRO 02157Q109 $13.2M 0.40% 500,000 SH
31 X4 PHARMACEUTICALS INC XFOR 98420X202 $9.0M 0.27% 1,934,253 SH
32 RESEARCH ALLIANCE CORP III RACC G75226103 $3.2M 0.10% 300,000 SH
33 INMED PHARMACEUTICALS INC INM 457637700 $50.7K 0.00% 32,685 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $3.30B 33 0001615982-26-000015
2026-03-31 2026-05-15 $2.68B 33 0001615982-26-000011
2025-12-31 2026-02-17 $2.02B 27 0001615982-26-000005
2025-09-30 2025-11-14 $1.78B 33 0001615982-25-000006
Filer Information
Address
7 BRYANT PARK
23RD FLOOR
NEW YORK, NY 10018
Phone
(650) 475-3734
Filing Manager
Venrock Adviser, LLC
NEW YORK, NY
Signatory
Sherman G. Souther
Authorized Signatory